isopropyl (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6- trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoate | 34362-74-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: isopropyl (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6- trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoate
• 英文别名: propan-2-yl (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoate
• CAS: 34362-74-8
• 化学式: C₂₃H₃₄O₂
• 分子量: 342.522
• InChiKey: AGRHKGOFKSUCLY-DXJCHIHNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.4
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  维A酸 、 异丙醇 在 (E)-1,2-Di(pyridin-4-yl)diazene 、 三苯基膦 作用下， 以 乙腈 为溶剂， 反应 12.0h， 生成 isopropyl (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6- trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoate
  参考文献：
  名称：

  少年激素类视黄醇类似物的合成

  摘要：

  作为旨在设计对蚊子幼虫具有活性的新化学物质的合作研究项目的一部分，我们寻求了可得的原材料以及用于制备大量活性物质的有效合成方法。为此，我们选择了视黄酸，它的功能与青少年激素相近。通过该分子，我们开发了酯和三氟甲基酮的合成方法，该方法合成快，收率高。

  DOI：

  10.1002/aoc.3736

文献信息

• [EN] COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS<br/>[FR] COMPOSÉS ET MÉTHODES POUR LE TRAITEMENT DE TROUBLES OCULAIRES
  申请人：AZURA OPHTHALMICS LTD

  公开号：WO2022084747A1

  公开（公告）日：2022-04-28

  Described herein are compositions and methods for the treatment or prevention of ocular surface disorders including meibomian gland dysfunction, blepharitis, dry eye disease and other inflammatory and/or infectious diseases of the anterior surface of the eye(s). Said compositions and methods comprise keratolytic conjugates which demonstrate keratolytic activity, and anti- inflammatory or other desirable activities. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from ocular surface disorders.

  本文描述了一种治疗或预防眼表面疾病的组合物和方法，包括睑腺功能障碍、睑缘炎、干眼病和其他前表面炎症和/或感染性眼疾。所述的组合物和方法包括角质溶解偶联物，其表现出角质溶解活性，以及抗炎或其他理想活性。将所述组合物局部给药于眼睑边缘或周围区域，可为患有眼表面疾病的患者提供治疗益处。
• Additives enhancing topical applications of therapeutic agents
  申请人：TriStrata, Inc.

  公开号：US20030017130A1

  公开（公告）日：2003-01-23

  Preventive as well as therapeutic treatment to alleviate cosmetic conditions and symptoms of dermatologic disorders with amphoteric compositions containing alpha hydroxyacids, alpha ketoacids, related compounds or polymeric forms of hydroxyacids is disclosed. The cosmetic conditions and the dermatologic disorders in which the amphoteric compositions and the polymeric compounds may be useful include dry skin, dandruff, acne, keratoses, psoriasis, eczema, pruritus, age spots, lentigines, melasinas, wrinkles, warts, blemished skin, hyperpigmented skin, kyperkeratotic skin, inflammatory dermatoses, skin changes associated with aging, and skin requiring cleansers.

  本发明公开了含有α-羟基酸、α-酮酸、相关化合物或羟基酸聚合形式的两性组合物的预防和治疗方法，以缓解美容状况和皮肤病症状。两性组合物和聚合化合物可用于治疗的美容病症和皮肤病包括皮肤干燥、头皮屑、痤疮、角化病、牛皮癣、湿疹、瘙痒症、老年斑、色斑、黑斑、皱纹、疣、瑕疵皮肤、色素沉着皮肤、角化过度皮肤、炎症性皮肤病、与衰老有关的皮肤变化以及需要清洁剂的皮肤。
• A Simple, General and Efficient Method for O and N-Retinoylation. Application to The Synthesis of 2-Retinoyl-Lecithin
  作者：Charles Sangmam、Jean-Yves Winum、Marc Lucas、Jean-Louis Montero、Claude Chavis

  DOI：10.1080/00397919808004874

  日期：1998.8

  The synthesis of the new 1-stearoyl-2-retinoyl-glycero-3-phosphorylcholine by coupling of retinoic acid and lysolecithin with DCC-DMAP (1.2 eq.) is reported. This method is applied to O and N-retinoylation of uncharged organic substrates such as aliphatic alcohols, free hydroxyl anomeric sugars, aromatic amines and C-protected alpha-aminoacids.
• DERMAL FILLER HYDROGELS WITH VITAMIN A/CYCLODEXTRIN INCLUSION COMPLEXES
  申请人：ALLERGAN, INC.

  公开号：EP2903588A2

  公开（公告）日：2015-08-12
• ALL-TRANS RETINOID ESTERS AS ACTIVE PHARMACEUTICAL INGREDIENTS, ORAL AND TOPICAL DOSAGE FORM COMPOSITIONS THEREOF, AND METHODS OF TREATING SKIN CONDITIONS THEREOF
  申请人：Clagett-Dame Margaret

  公开号：US20110003892A1

  公开（公告）日：2011-01-06

  Active pharmaceutical ingredients being retinoic acid ester compounds including all- trans-retinoic acid tent-butyl ester, all-trans-retinoic acid iso-butyl ester, all-trans-retinoic acid iso-propyl ester, all-trans-retinoic acid sec-butyl ester, and, all-trans-retinoic acid 1-adamantyl ester, oral and topical dosage form compositions thereof, and methods of treating various skin conditions thereof.